Publications by authors named "L Panther"
Article Synopsis
- Researchers developed a new method to synthesize 9 core-functionalised naphthalene diimide (c-NDI) compounds using a three-step, solvent-free process that activates chemicals mechanically.
- They achieved selective dibromination of naphthalenetetracarboxylic dianhydride in a vibratory ball mill, producing a key intermediate (2,6-dibromonaphthalenediimide) quickly and efficiently within 5 hours, significantly faster than traditional methods.
- The study also successfully executed rapid Heck-type cross coupling reactions with various styrene residues, resulting in good yields of c-NDIs without the need for extra heating or solvents, making the process robust against environmental conditions.
Article Synopsis
- mRNA-1647 is an experimental mRNA vaccine targeting cytomegalovirus (CMV) that stimulates immune responses by encoding specific viral proteins.
- In a phase 1 trial, healthy adults who received three doses developed strong neutralizing antibodies and increased memory B cells, which persisted for months.
- The vaccine effectively triggered robust T-cell responses, indicating its potential for further clinical development to combat CMV, a virus that poses risks, especially to vulnerable populations.
Article Synopsis
- A phase 1 trial tested the safety and immune response of an mRNA-based vaccine, mRNA-1647, for cytomegalovirus (CMV) in both seronegative and seropositive adults.
- 154 participants were involved, with most reporting mild to moderate adverse reactions and no serious side effects noted.
- The results indicated that mRNA-1647 was safe and effective in stimulating both antibody and cell-mediated immune responses in participants.
Background: MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated approximately 50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting that efforts to improve this vaccine design might yield a vaccine suitable for licensure.
Methods: A messenger RNA (mRNA)-based vaccine candidate encoding HCMV gB and pentameric complex (PC), mRNA-1647, is currently in late-stage efficacy trials. However, its immunogenicity has not been compared to the partially effective gB/MF59 vaccine.
Cytomegalovirus (CMV) infection during pregnancy may result in long-term health problems for children with congenital CMV (cCMV). Currently, no prevention or treatment interventions are approved by the Food and Drug Administration for a cCMV indication. Healthcare provider and public awareness is low, and formal clinical practice guidelines and local practice patterns vary.
View Article and Find Full Text PDF